LoadingLoadingLoading36 funds hold it.Insiders net selling.
Net selling: insiders sold $96K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Aug 26, 2026
Period ending
Jul 31, 2026
Earnings per share
$1.49 expected
Estimates as of Nov 7, 2026
EPS expected
$1.71 to $1.74
Revenue expected
17 analysts
Last 30 days
Analysts raising estimates
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Jul 31, 2026Reported Aug 26, 2026 | $1.62est. $1.49 | +9.01%beat | $1.88BSEC filing | +8.1%from $1.74B |
| Apr 30, 2026Reported May 27, 2026 | $1.49est. $1.41 | +5.80%beat | $1.83BCompany release | +10.0%from $1.67B |
| Jan 31, 2026Reported Feb 25, 2026 | $1.36est. $1.37 | -0.60%in line | $1.80BSEC filing | +7.0%from $1.68B |
| Oct 31, 2025Reported Nov 24, 2025 | $1.59est. $1.58 | +0.37%in line | $1.86BAlpha Vantage | +9.4%from $1.70B |
| Jul 31, 2025Reported Aug 27, 2025 | $1.37est. $1.37 | +0.00%in line | $1.74BSEC filing | +10.1%from $1.58B |
| Apr 30, 2025Reported May 28, 2025 | $1.31est. $1.26 | +3.97%beat | $1.67BSEC filing | +6.0%from $1.57B |
| Jan 31, 2025Reported Feb 26, 2025 | $1.31est. $1.27 | +3.15%beat | $1.68BSEC filing | +1.4%from $1.66B |
| Oct 31, 2024Reported Nov 25, 2024 | $1.46est. $1.41 | +3.55%beat | $1.70BAlpha Vantage | +0.8%from $1.69B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.86B | $1.80B | $1.83B | $1.88B |
| Cost of what it sold | $897.0M | $852.0M | $826.0M | $836.0M |
| Gross profit | $964.0M | $946.0M | $1.01B | $1.04B |
| What it spent | ||||
| Research and development | $119.0M | $117.0M | $126.0M | $123.0M |
| Sales and admin | $428.0M | $476.0M | $465.0M | $475.0M |
| Other operating costs | -$26.0M | — | $19.0M | — |
| Total operating expenses | $521.0M | $593.0M | $610.0M | $598.0M |
| What was left | ||||
| Operating profit | $443.0M | $353.0M | $399.0M | $444.0M |
| Interest on debt | $27.0M | $25.0M | $25.0M | $29.0M |
| Profit before tax | $442.0M | $364.0M | $408.0M | $444.0M |
| Tax | $8.0M | $59.0M | $69.0M | $82.0M |
| Net profit | $434.0M | $305.0M | $339.0M | $362.0M |
| EBITDA | $540.0M | $456.0M | $500.0M | $539.0M |
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Proscia Joins Agilent in $240 Million Pathology Software Deal
BullishNov 6Form 8K Agilent Technologies For: 6 November By Investing.com
NeutralNov 6Form 8K Agilent Technologies For: 6 November By Investing.com
NeutralNov 6In Brief This Week: Personalis, IntelliGenome, Agilent, Bio-Techne, Labcorp, TwinStrand, More
NeutralNov 6How Investors May Respond To Agilent (A) New Mass Spectrometer Launch
Leans bullishNov 6Twist Bioscience Stock Sinks as Bear Cave Raises Valuation Concerns
NeutralNov 5Here’s How Much You Would Have Made Owning Agilent Technologies Stock In The Last 10 Years
BullishNov 5Agilent Closes $240M Acquisition of Digital Pathology Software Maker Proscia
BullishNov 5
